Collegium Pharma (COLL) Appoints Nancy S. Lurker to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
Collegium Appoints Nancy S. Lurker to its Board of Directors
February 5, 2025 8:00 AM ESTSTOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025.
Collegium is pleased to welcome Nancy to our Board of Directors, said Mike Heffernan, Founder and Chairman of the Board of Collegium. Nancys expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.
This is a... More
